1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
January 2023 in “Mastology” Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
June 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
Hair transplant worked for a patient with a specific scalp condition after breast cancer chemotherapy.
September 2016 in “Oncology times” Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.
March 2010 in “Ejc Supplements” CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
March 2010 in “Ejc Supplements” Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.
June 1995 in “International Journal of Gynecology & Obstetrics” Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.
April 2023 in “International Journal of Women's Dermatology” Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
68 citations,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
59 citations,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
32 citations,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
31 citations,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
30 citations,
February 1994 in “Journal of Cutaneous Pathology” A woman's hair loss was initially mistaken for a common hair loss condition but was later found to be caused by breast cancer cells in her scalp.
22 citations,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
18 citations,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.
12 citations,
May 2010 in “PubMed” No definitive link between finasteride and male breast cancer, but further research is needed.
9 citations,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
9 citations,
January 2014 in “Annals of Dermatology” Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
9 citations,
February 2012 in “Social Semiotics” The document concludes that modern photo stories help represent and challenge how breast cancer affects women's identities and societal norms.
8 citations,
December 2017 in “Cancer Medicine” Finasteride use may increase the risk of male breast cancer.
7 citations,
March 2019 in “Cancer Epidemiology, Biomarkers & Prevention” Finasteride use is not clearly linked to an increased risk of male breast cancer.
7 citations,
May 2016 in “SpringerPlus” Some breast cancer patients on hormone therapy experience hair loss, and treatments like certain topical inhibitors and supplements may help without harming their cancer prognosis.
4 citations,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.